We are live on
!
Find out more
MCMC
Matrix Capital Management Company Portfolio holdings
AUM
$46.3M
1-Year Est. Return
114.38%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
+114.38%
3 Year Est. Return
+245.06%
5 Year Est. Return
+259.19%
10 Year Est. Return
+1,887.32%
AUM
$2.15B
AUM Growth
+$56.7M
(+2.7%)
Cap. Flow
-$136M
Cap. Flow
% of AUM
-6.31%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
2
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GlobalFoundries
GFS
|
+$94.3M |
| 2 |
ADAP
Adaptimmune Therapeutics
ADAP
|
+$35.8M |
| 3 |
Adaptive Biotechnologies
ADPT
|
+$3.33M |
| 4 |
Perimeter Solutions
PRM
|
+$2.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 91.5% |
| 2 | Healthcare | 4.61% |
| 3 | Materials | 3.89% |
Similar funds
CM
RRC
NPCM
FCM
PCM
EGI
IPHI
SM
Matrix Capital Management Company's Q4 2024 Portfolio in Review
As of Q4 2024, Matrix Capital Management Company held 7 positions worth $2.15B, up 2.7% from $2.09B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Matrix Capital Management Company withdrew a net $136M in Q4 2024, closing 2 positions and reducing 2 holdings. Its most notable exit was Adaptimmune Therapeutics, an estimated $35.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 91% of assets, up from 88% a quarter earlier, followed by Healthcare and Materials.
- Matrix Capital Management Company's biggest Q4 2024 reduction was GlobalFoundries, cutting an estimated $94.3M.
- Matrix Capital Management Company fully exited Adaptimmune Therapeutics in Q4 2024, selling an estimated $35.8M.
- Matrix Capital Management Company's ten largest holdings make up 100% of its $2.15B portfolio in Q4 2024.
- Matrix Capital Management Company opened 0 new positions and closed 2 in Q4 2024.
- Matrix Capital Management Company's portfolio value rose 2.7% quarter-over-quarter to $2.15B.
Based on Matrix Capital Management Company's 13F filing for Q4 2024, filed 13 Feb 2025.